




EY Entrepreneur
of the year-2013



FROST & SULLIVAN
Best Practices-2013



Business today/YES bank
Excellence Awards-2013

Eris
Eris Lifesciences Ltd.

22nd November 2017

To,

National Stock Exchange of India Ltd.

Exchange Plaza, Plot No. C/1, G-Block,

Bandra-Kurla Complex, Bandra (E), Mumbai

Kind Attn: Mr. Kautuk Upadhyay, Manager

Ref No.: Your letter dated 20th November, 2017 bearing reference no NSE/LIST/FR/2977

Sub: Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir,

We refer to the contents of your above referred letter and clarify the matter as under:

1. Our Company has been listed on the National Stock Exchange of India Limited and the BSE Limited for the first time on 29th June 2017 ("**Listing Date**");
2. Being an unlisted entity prior to the Listing Date, we were neither required to prepare nor publish the quarterly/half yearly financial results in respect of any period prior to the Listing Date. You may appreciate that the requirement of preparation and publication of the quarterly/half yearly financial results typically applies to the listed entities only in terms of the Securities and Exchange Board Of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("**LODR**");
3. The quarterly/half yearly financial results of our company in respect of the quarter/half year ended September 2017 ("**Reporting Period Results**") are prepared as per IND-AS and have been duly approved by the Board of Directors of our Company ("**Board**") and has also been duly subjected to the limited review of our Statutory Auditors before its eventual publication, in terms of the requirements of the LODR;

Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179402 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in


CIN: L24232GJ2007PLC049867



EY Entrepreneur
of the year-2013



FROST & SULLIVAN
Best Practices-2013



Business today/YES bank
Excellence Awards-2013

Eris
Eris Lifesciences Ltd.


4. The comparative quarterly/half yearly financial results in respect of the quarter/half year ended September 2016 ("**Comparative Period Results**") have also been prepared and published as per IND-AS only and have similarly undergone the respective scrutiny of the Board as is applicable to the Reporting Period Results under the LODR.
5. Based on our aforesaid submissions, you may kindly appreciate that the Comparative Period Results were never prepared or published as per IND-GAAP. Hence, these Comparative Period Results are not and have never been at variance with any of our previously reported results. Therefore, in our view, no reconciliation is necessary nor desirable and should best be avoided in the interest maintaining clarity about the reported figures as both are already based on IND-AS and are, even otherwise, compliant with LODR.

We believe that we have been able to resolve the raised query to your complete satisfaction. We are available to answer any further queries that you may have in this regard.

Yours truly,

Thanking you,

For Eris Lifesciences Limited


Sachin Shah

Chief Financial Officer

Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179402 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867